ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
ELITE PHARMACEUTICALS INC /NV/
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026
- Market cap
- $283.02M
- P/E (TTM)
- 5.0
- Dividend yield
- –
ELITE PHARMACEUTICALS INC /NV/ revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Business Segment [Member] | – | – | – | – | – | – | $17.99M | $7.57M | $7.46M | $9.64M | – | – |
| New Drug Applications [Member] | – | $0 | $0 | $0 | – | $166.17K | $1.00M | $1.00M | $1.00M | – | – | – |
| Abbreviated New Drug Applications [Member] | – | $84.04M | $56.63M | $34.16M | $32.26M | $25.21M | $16.99M | $6.57M | $6.46M | – | – | – |
| Operating income | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Business Segment [Member] | – | $32.12M | $19.47M | $10.39M | $10.74M | $6.66M | $2.02M | -$4.24M | -$4.85M | -$3.94M | – |
| New Drug Applications [Member] | – | – | – | – | – | $142.81K | $153.78K | $122.96K | -$3.02M | – | – |
| Abbreviated New Drug Applications [Member] | – | $32.12M | $19.47M | $10.39M | $10.74M | $6.51M | $1.87M | -$4.36M | -$1.83M | – | – |
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Manufacturing [Member] | $147.81M | $81.99M | $54.12M | – | – | – | – | – | – | – | 99.3% | +80.3% |
| Manufacturing Fees [Member] | $147.81M | $81.99M | – | – | – | – | – | – | – | – | 99.3% | +80.3% |
| Scheduled Products Manufacturing Fees [Member] | $141.47M | $74.76M | – | – | – | – | – | – | – | – | 95.0% | +89.2% |
| Indirect Sales to Wholesalers [Member] | $82.54M | $33.98M | – | – | – | – | – | – | – | – | 55.4% | +142.9% |
| Direct Sales to Wholesalers [Member] | $65.27M | $48.01M | – | – | – | – | – | – | – | – | 43.8% | +36.0% |
| Unscheduled Products Manufacturing Fees [Member] | $6.34M | $7.23M | – | – | – | – | – | – | – | – | 4.3% | -12.2% |
| Licensing [Member] | $1.06M | $2.06M | $2.50M | – | – | – | – | – | – | – | 0.7% | -48.5% |
| Unscheduled Products Licensing Fees [Member] | $594.49K | $1.81M | – | – | – | – | – | – | – | – | 0.4% | -67.1% |
| Scheduled Products Licensing Fees [Member] | $465.51K | $248.79K | – | – | – | – | – | – | – | – | 0.3% | +87.1% |
| Health Care [Member] | – | – | – | – | – | – | – | – | – | $33.60M | – | – |
By region
From the segment and revenue-disaggregation notes of Elite Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.